Verified source brief

STAT+: Capricor Therapeutics accuses Nippon Shinyaku of slow-walking plans on Duchenne drug

Capricor Therapeutics has accused Nippon Shinyaku and its U.S. subsidiary of botching the rollout of a Duchenne muscular dystrophy treatment.

Illustrated brief card for a source-linked news item

Source Wire Desk Briefs Source-linked brief

Source brief

Capricor Therapeutics has accused Nippon Shinyaku and its U.S. subsidiary of botching the rollout of a Duchenne muscular dystrophy treatment.

Original source

This is a source-linked brief from STAT. Read the original item at STAT+: Capricor Therapeutics accuses Nippon Shinyaku of slow-walking plans on Duchenne drug.

Attribution

VINI publishes the headline, source metadata, short feed summary, topic labels, and outbound source link for reader discovery. The full article remains with the original publisher.

Published by source: 2026-05-08T18:32:59+00:00

This source-linked brief summarizes publisher-provided metadata and links to the original report. VINI does not republish third-party article bodies without rights clearance. 1 source listed.

Source links

STAT+: Capricor Therapeutics accuses Nippon Shinyaku of slow-walking plans on Duchenne drugSTAT - 2026-05-08T18:32:59+00:00

Reader comments

Moderated discussion

Account access

Comments are open to authenticated approved accounts, screened for spam and abuse, and published only after newsroom moderation unless editors change the story control.

Loading comments.